Liu M - Search Results

1

Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant.

Liu M, Kang S, Ray S, Jackson J, Zaitsev AD, Gerber SA, Cuny GD, Glicksman MA. Liu M, et al. Biochemistry. 2011 Nov 1;50(43):9399-408. doi: 10.1021/bi201173d. Epub 2011 Oct 7. Biochemistry. 2011. PMID: 21961647 Free PMC article.

2

Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors.

Liu M, Choi S, Cuny GD, Ding K, Dobson BC, Glicksman MA, Auerbach K, Stein RL. Liu M, et al. Biochemistry. 2008 Aug 12;47(32):8367-77. doi: 10.1021/bi800732v. Epub 2008 Jul 18. Biochemistry. 2008. PMID: 18636751

3

Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.

Liu M, Dobson B, Glicksman MA, Yue Z, Stein RL. Liu M, et al. Biochemistry. 2010 Mar 9;49(9):2008-17. doi: 10.1021/bi901851y. Biochemistry. 2010. PMID: 20146535 Free PMC article.

4

Kinetic mechanistic studies of Cdk5/p25-catalyzed H1P phosphorylation: metal effect and solvent kinetic isotope effect.

Liu M, Girma E, Glicksman MA, Stein RL. Liu M, et al. Biochemistry. 2010 Jun 15;49(23):4921-9. doi: 10.1021/bi100244j. Biochemistry. 2010. PMID: 20491486 Free PMC article.

5

Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors.

Liu M, Poulose S, Schuman E, Zaitsev AD, Dobson B, Auerbach K, Seyb K, Cuny GD, Glicksman MA, Stein RL, Yue Z. Liu M, et al. Anal Biochem. 2010 Sep 15;404(2):186-92. doi: 10.1016/j.ab.2010.05.033. Epub 2010 Jun 2. Anal Biochem. 2010. PMID: 20566370 Free PMC article.

6

Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

Ray S, Liu M. Ray S, et al. Among authors: liu m. Future Med Chem. 2012 Sep;4(13):1701-13. doi: 10.4155/fmc.12.110. Future Med Chem. 2012. PMID: 22924508 Free PMC article. Review.

7

Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.

Liu M, Bender SA, Cuny GD, Sherman W, Glicksman M, Ray SS. Liu M, et al. Biochemistry. 2013 Mar 12;52(10):1725-36. doi: 10.1021/bi3012077. Epub 2013 Mar 1. Biochemistry. 2013. PMID: 23379419 Free PMC article.

8

The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.

Ray S, Bender S, Kang S, Lin R, Glicksman MA, Liu M. Ray S, et al. Among authors: liu m. J Biol Chem. 2014 May 9;289(19):13042-53. doi: 10.1074/jbc.M113.537811. Epub 2014 Apr 2. J Biol Chem. 2014. PMID: 24695735 Free PMC article.

9

Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking.

Lang CA, Ray SS, Liu M, Singh AK, Cuny GD. Lang CA, et al. Among authors: liu m. Bioorg Med Chem Lett. 2015 Jul 1;25(13):2713-9. doi: 10.1016/j.bmcl.2015.04.027. Epub 2015 Apr 16. Bioorg Med Chem Lett. 2015. PMID: 25998502

10

LRRK2 Facilitates tau Phosphorylation through Strong Interaction with tau and cdk5.

Shanley MR, Hawley D, Leung S, Zaidi NF, Dave R, Schlosser KA, Bandopadhyay R, Gerber SA, Liu M. Shanley MR, et al. Among authors: liu m. Biochemistry. 2015 Aug 25;54(33):5198-208. doi: 10.1021/acs.biochem.5b00326. Epub 2015 Aug 13. Biochemistry. 2015. PMID: 26268594

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46,093 results

Search Page

Filters